omni
nkf
Feraheme® (ferumoxytol) Injection For Intravenous (IV) Use

Feraheme® (ferumoxytol) Injection For Intravenous (IV) Use from AMAG Pharmeceuticals

1100 Winter Street Waltham, MA 02451

Company Profile
In the United States, Feraheme (ferumoxytol) Injection is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). Feraheme received marketing approval from the US Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the US shortly thereafter.
see

YOU MIGHT ALSO BE INTERESTED IN

OTHER Vendor ShowcaseS